Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Optimal Treatment for Women with Ovarian Cancer

  • Lucas Minig
  • Edward L. Trimble
  • Nicoletta Colombo
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6976-5

Definition

In the developed world, ovarian cancer is the leading cause of death from gynecologic malignancies. More than 90 % of ovarian cancers are epithelial carcinomas, while germ cell and stromal cancers account for about 5–7 % ovarian cancer. The base of evidence is strongest for epithelial ovarian cancer and much weaker for ovarian germ cell and stromal cancers.

Characteristics

Screening and Early Diagnosis

To date, there is no effective screening algorithm for epithelial ovarian cancer. Over 70 % of women diagnosed with epithelial ovarian cancer present with advanced-stage disease, with cancer extending outside the ovaries and pelvis (International Federation of Obstetricians and Gynecologists (FIGO) stage III–IV disease). Most cases of early-stage ovarian cancer(FIGO stages I–II) are found either incidentally or due to symptoms of adnexal enlargement. Recent studies suggest that women diagnosed with advanced ovarian cancer do experience a prodrome of symptoms that warrant...

Keywords

Overall Survival Ovarian Cancer Epithelial Ovarian Cancer Ovarian Serous Carcinoma Ovarian Clear Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Goff BA, Mandel LS, Drescher CW et al (2007) Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109:221–227CrossRefPubMedGoogle Scholar
  2. Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet 374:1331–1338CrossRefPubMedGoogle Scholar
  3. Kyrigiou M, Salanti G, Pavlidid N et al (2006) Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 98:1655–1663CrossRefGoogle Scholar
  4. Mackay H, Brady MF, Oza AM et al (2010) Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 20:945–952CrossRefPubMedGoogle Scholar
  5. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. MRC OV05; EORTC 55955 investigators. Lancet. 376(9747):1155–1163.Google Scholar
  6. Vergote I, Trope CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953CrossRefPubMedGoogle Scholar

See Also

  1. (2012) Adjuvant. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 75. doi:10.1007/978-3-642-16483-5_107Google Scholar
  2. (2012) CA125. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 577–578. doi:10.1007/978-3-642-16483-5_761Google Scholar
  3. (2012) Carboplatin. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 641. doi:10.1007/978-3-642-16483-5_833Google Scholar
  4. (2012) Computed Tomography. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 964–965. doi:10.1007/978-3-642-16483-5_1295Google Scholar
  5. (2012) Cytoreductive Surgery. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1057. doi:10.1007/978-3-642-16483-5_1489Google Scholar
  6. (2012) Dose-Dense. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1155. doi:10.1007/978-3-642-16483-5_6981Google Scholar
  7. (2012) Doxorubicin. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1159. doi:10.1007/978-3-642-16483-5_1722Google Scholar
  8. (2012) Endometrioid Carcinoma. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1234. doi:10.1007/978-3-642-16483-5_6966Google Scholar
  9. (2012) Epithelial Ovarian Cancer. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1292. doi:10.1007/978-3-642-16483-5_6952Google Scholar
  10. (2012) Hazard Ratio. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1633. doi:10.1007/978-3-642-16483-5_6977Google Scholar
  11. (2012) Human Chorionic Gonadotropin. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 1752–1753. doi:10.1007/978-3-642-16483-5_6914Google Scholar
  12. (2012) Inhibin. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1864. doi:10.1007/978-3-642-16483-5_3051Google Scholar
  13. (2012) Magnetic Resonance Imaging. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2136. doi:10.1007/978-3-642-16483-5_3496Google Scholar
  14. (2012) Neoadjuvant. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2472. doi:10.1007/978-3-642-16483-5_4003Google Scholar
  15. (2012) Ovarian Cancer Staging. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2711. doi:10.1007/978-3-642-16483-5_6978Google Scholar
  16. (2012) Ovarian Clear Cell Carcinoma. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2711. doi:10.1007/978-3-642-16483-5_6965Google Scholar
  17. (2012) Salpingo-Oophorectomy. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3332. doi:10.1007/978-3-642-16483-5_6903Google Scholar
  18. (2012) Sex-Cord Stromal Tumors. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 3395–3396. doi:10.1007/978-3-642-16483-5_5273Google Scholar
  19. (2012) Surgical Debulking. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3575. doi:10.1007/978-3-642-16483-5_5598Google Scholar
  20. (2012) Topotecan. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3730. doi:10.1007/978-3-642-16483-5_6948Google Scholar
  21. (2012) Ultrasound. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3836. doi:10.1007/978-3-642-16483-5_6097Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Lucas Minig
    • 1
  • Edward L. Trimble
    • 2
  • Nicoletta Colombo
    • 3
  1. 1.Gynecologic DepartmentValencian Institute of Oncology (IVO)ValenciaSpain
  2. 2.Department of Health and Human ServicesNational Cancer Institute, National Institutes of HealthBethesdaUSA
  3. 3.Istituto Europeo di OncologiaMilanItaly